全文获取类型
收费全文 | 314篇 |
免费 | 17篇 |
出版年
2021年 | 4篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 2篇 |
2015年 | 9篇 |
2014年 | 7篇 |
2013年 | 15篇 |
2012年 | 14篇 |
2011年 | 5篇 |
2010年 | 9篇 |
2009年 | 14篇 |
2008年 | 8篇 |
2007年 | 11篇 |
2006年 | 14篇 |
2005年 | 10篇 |
2004年 | 12篇 |
2003年 | 4篇 |
2002年 | 3篇 |
2001年 | 10篇 |
2000年 | 14篇 |
1999年 | 17篇 |
1998年 | 8篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1992年 | 13篇 |
1991年 | 10篇 |
1990年 | 14篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 8篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1982年 | 3篇 |
1981年 | 6篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1969年 | 2篇 |
1966年 | 2篇 |
1961年 | 2篇 |
1959年 | 2篇 |
1955年 | 3篇 |
1952年 | 2篇 |
1948年 | 2篇 |
1927年 | 2篇 |
1899年 | 1篇 |
排序方式: 共有331条查询结果,搜索用时 0 毫秒
1.
2.
G Ciabattoni J Maclouf F Catella G A FitzGerald C Patrono 《Biochimica et biophysica acta》1987,918(3):293-297
Because of the discrepancy between the capacity of platelets to synthesize thromboxane B2 ex vivo and the actual synthetic rate in vivo, measurement of thromboxane B2 in plasma is highly influenced by sampling-related artifacts. We have developed and validated a radioimmunoassay for a major enzymatic derivative of thromboxane B2 with an extended plasma half-life, i.e., 11-dehydrothromboxane B2. The binding of the tracer is displaced by as low as 1 pg/ml of the homologous ligand, with a high degree of specificity for the open ring structure as well as for the omega side-chain. This method can detect changes in the plasma concentration and urinary excretion of 11-dehydrothromboxane B2 associated with stimulated short-term increases of thromboxane B2 secretion in the human circulation. 相似文献
3.
4.
5.
6.
7.
8.
9.
Niacin (nicotinic acid) has been used for decades as a lipid-lowering drug. The clinical use of niacin to treat dyslipidemic conditions is limited by its side effects. Niacin, along with fibrates, are the only approved drugs which elevate high density lipoprotein cholesterol (HDLc) along with its effects on low density lipoprotein cholesterol (LDLc) and triglycerides. Whether niacin has a beneficial role in lowering cardiovascular risk on the background of well-controlled LDLc has not been established. In fact, it remains unclear whether niacin, either in the setting of well-controlled LDLc or in combination with other lipid-lowering agents, confers any therapeutic benefit and if so, by which mechanism. The results of recent trials reject the hypothesis that simply raising HDLc is cardioprotective. However, in the case of the clinical trials, structural limitations of trial design complicate their interpretation. This is also true of the most recent Heart Protection Study 2-Treatment of HDLc to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial in which niacin is combined with an antagonist of the D prostanoid (DP) receptor. Human genetic studies have also questioned the relationship between cardiovascular benefit and HDLc. It remains to be determined whether niacin may have clinical utility in particular subgroups, such as statin intolerant patients with hypercholesterolemia or those who cannot achieve a sufficient reduction in LDLc. It also is unclear whether a potentially beneficial effect of niacin is confounded by DP antagonism in HPS2-THRIVE. 相似文献
10.